Overview

We were formed in 2014 by neuroscience researchers at the Swiss Federal Institute of Technology (EPFL). We are now headquartered at the High Tech Campus in Eindhoven, the Netherlands, with an office in Lausanne, Switzerland and a growing US team based in Boston, Massachusetts.

Meet the team

  • Dave Marver, CEO

    Dave Marver

    Chief Executive Officer

    Dave Marver joined ONWARD in July 2020. An accomplished chief executive and director with more than 25 years of international experience in public, private, and emerging companies, he combines expertise in medical and consumer technology, wearables, and health monitoring. Previously, Dave spent almost 15 years with Medtronic in a variety of leadership positions in the US and Europe, including Vice President roles in Sales, Marketing, Strategy, and Business Development. He then joined NASDAQ-listed Cardiac Science Corporation as CEO, before co-founding two start-ups. He holds a BA in Psychology from Duke University and an MBA from University of California Los Angeles.
  • John Murphy, PhD, CTO

    John Murphy, PhD

    Chief Technology Officer

    John Murphy has over 25 years of experience driving the development of medical implants and neurostimulation devices at LivaNova, Abbott, and Medtronic. His leadership expertise spans the continuum of R&D, with a focus on consumer-centric design, IP generation, and agile processes. Prior to joining ONWARD in 2020, John was the Chief Technology Officer of LivaNova Neuromodulation. He holds a BS in Electrical Engineering from the University of North Carolina at Charlotte and a PhD in Production Systems and Robotics from the Swiss Federal Institute of Technology (EPFL).
  • Lara

    Lara Smith Weber

    Chief Financial Officer

    Lara Smith Weber brings over 25 years of finance, accounting, and strategy experience with life science companies in the United States and Europe. She most recently served as CFO and Head of Commercial Financial Planning and Analysis for MorphoSys, Inc., based in Boston, USA. Prior to that, Lara held various finance leadership roles at MorphoSys AG, based in Munich, Germany. Her roles included Senior VP, Head of Controlling and Corporate Finance, where she led a US$239M NASDAQ IPO in 2018. Previously, Lara spent 7 years at Telefonica Germany in a variety of finance leadership positions and worked for consulting firm, Booz Allen Hamilton, in Zurich, Switzerland. Lara earned a BA in German Studies and both a BS and M.Sc. in Electrical Engineering from Stanford University in Palo Alto, USA. She also earned an MBA from IMD in Lausanne, Switzerland.

  • Grégoire Courtine, PhD, CSO

    Grégoire Courtine, PhD

    Chief Scientific Officer

    Prof. Grégoire Courtine is the co-founder of ONWARD and its Chief Scientific Officer as well as a Non-Executive Director. His ground-breaking research in neuroscience has been recognized by several prestigious prizes, including the Rolex Award, the Schellenberg Research Prize and the Chancellor’s Award of the University of California. Grégoire is a full professor of neuroscience and neurotechnology at the Swiss Federal Institute of Technology (EPFL) and Director of NeuroRestore, a research center at EPFL and the University Hospital of Lausanne that develops innovative therapies using neurostimulation and other approaches. He holds a PhD in Neurosciences from INSERM, Paris, and a PhD in Medicine from the University of Pavia, Italy.
  • Erika

    Erika Ross, PhD

    Vice President, Global Clinical & Regulatory

    Erika Ross brings extensive expertise in neuromodulation, with experience in clinical trial design and execution for class II and III neurostimulation technologies.  She joins ONWARD from Abbott Neuromodulation, where she was Director, Global Clinical & Applied Research. Previously, as Neuroscience Director at Cala Health, she managed the scientific research program that led to de novo clearance and launch of the company’s neurostimulation technology. She also brings outstanding relationships with researchers and clinicians, forged during her years as Deputy Director, Medical Device Innovation Accelerator, Department of Surgery, and Assistant Professor, Department of Neurologic Surgery at Mayo Clinic. Erika holds a BSc in Biology and Business and an MSc in Molecular Biology from the University of Denver and a PhD in Neuroscience from Mayo Clinic.

Recent News

14 Mar 23
ONWARD to Publish Full Year 2022 Financial Results and Host Webcast on March 28, 2023

EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA—March 14, 2023—ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced it will publish full year 2022 financial and operating results on Tuesday, March 28, 2023. Management will also host a webcast to discuss operational and financial highlights, as well as provide a business update, on March 28, 2023, at 14:00 CEST / 08:00 EDT.

13 Mar 23
ONWARD Does Not Hold Cash Deposits at Silicon Valley Bank

EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA – March 13, 2023 – ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced it does not hold cash deposits nor securities at Silicon Valley Bank (SVB).

23 Feb 23
ONWARD Receives New FDA Breakthrough Device Designations for Bladder Control, Alleviation of Spasticity, and Blood Pressure Regulation after Spinal Cord Injury
EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA—February 23, 2023 — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announced it has been granted Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the use of its ARC-EX platform for bladder control, alleviation of spasticity, and blood pressure regulation in people with SCI.
23 Jan 23
ONWARD Strengthens Leadership Team with Key Appointments in Clinical & Regulatory and Marketing
EINDHOVEN, the Netherlands, LAUSANNE, Switzerland, and BOSTON, MA USA—January 23, 2023 — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today announced two key

Financial Calendar

Recent Filings

ESG Information

Information is coming soon